Drugs / pirimiphos-methyl
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02610400 | Feb 2016 → Dec 2017 | malaria | University of California, San Francisco | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pirimiphos-methyl | “RACD involved rapid diagnostic testing and treatment with artemether-lumefantrine and single-dose primaquine, rfMDA involved presumptive treatment with artemether-lumefantrine,...” PMID 32334702 ↗ Apr 2020 |
| Known as | Actellic 300 CS | “pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate” NCT02610400 ↗ |
| Modality | Small molecule | — CHEMBL1886047 ↗ |
| Route | Other | “indoor residual spraying with pirimiphos-methyl” PMID 32334702 ↗ Apr 2020 |